Diabetic Retinopathy News and Research

RSS
In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Photon etc. announces the launch of IRIS, an innovative Retinal Hyperspectral Imaging system

Photon etc. announces the launch of IRIS, an innovative Retinal Hyperspectral Imaging system

UH's Eye Institute receives $5M Elisabeth Severance Prentiss Foundation gift

UH's Eye Institute receives $5M Elisabeth Severance Prentiss Foundation gift

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

IRIDEX announces data from MicroPulse laser therapy study on DME

IRIDEX announces data from MicroPulse laser therapy study on DME

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

JDC receives NIDDK grant for research into diabetic retinopathy, kidney disease

JDC receives NIDDK grant for research into diabetic retinopathy, kidney disease

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

U-M researchers to study new approach in halting downward spiral of diabetes

U-M researchers to study new approach in halting downward spiral of diabetes

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

DMEI dedicates new $46M research and clinical facility

DMEI dedicates new $46M research and clinical facility

JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME

JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME

New collaboration reinforces Sanofi's translational discovery platform for retinal diseases

New collaboration reinforces Sanofi's translational discovery platform for retinal diseases

Lucentis receives Health Canada approval to treat vision loss from DME

Lucentis receives Health Canada approval to treat vision loss from DME

IQWiG publishes results of literature search on DMP for diabetes mellitus type 1

IQWiG publishes results of literature search on DMP for diabetes mellitus type 1

KalVista raises £8 million in series A round of funding

KalVista raises £8 million in series A round of funding

Activus to receive NEDO grant for 'Development of Innovative Ophthalmic Solutions'

Activus to receive NEDO grant for 'Development of Innovative Ophthalmic Solutions'

Lucentis receives Health Canada approval for treatment of retinal vein occlusion

Lucentis receives Health Canada approval for treatment of retinal vein occlusion

Patients with diabetes, hypertension more likely to develop open-angle glaucoma

Patients with diabetes, hypertension more likely to develop open-angle glaucoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.